Paul K. Paik, MD
Alectinib (Alecensa) is the preferred frontline treatment for patients with ALK
-positive metastatic non–small cell lung cancer (NSCLC), but the potential FDA approval of lorlatinib may shift the landscape once again. The problem, says Paul K. Paik, MD, is that physicians are unable to pinpoint exactly how.
In February 2018, the FDA granted a priority review for lorlatinib for use in patients with ALK
-positive metastatic NSCLC who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs). Phase II data submitted by Pfizer showed an overall response rate (ORR) of 69% in ALK
-positive patients who had received crizotinib (Xalkori), then the frontline standard of care, with or without chemotherapy.
... to read the full story